Futura Medical Share Discussion Threads

[j777j] 02/7/2019 14:15

There is even a chance we could get results in November.June last patient recruited3.months trial so sep.One month to analyse data Oct.Gla.

[bioking] 02/7/2019 14:12

slaccs , in the last couple of years we were in early stage of the MED program now we are just 3 or 4 months away from Phase 3 readout its now different time . Thats why Investors should never invest in early stage pharma stock ony in those who have already phase 3 programs ongoing and are close to clinical results if you like to make money.

[j777j] 02/7/2019 13:53

I only post what I find and at the moment Liberum see 140p upside based on very conservative numbers. The $90 million upfront and milestone payments were from former house broker Singer N+1 and it is they who also forecast at 15% royalty rate. I am waiting for the share price to return to 56p as next level,which is pretty close to Liberum's 60p.

[slaccs] 02/7/2019 13:42

J777J - Any chance of some evidence behind all of your ramping or are you JB? Because nothing he has said in the last couple of years has ever come to anything. Just empty promise after empty promise. I would love for someone to prove me wrong.

[2cbg] 02/7/2019 13:29

bg23 - at times by selling I did not want to miss a potential opportunity and at other times the value of my shares was so small it was barely worth selling. In recent weeks I've had a few small but successful spreadbets. I'm sticking at the moment. We'll both be happy if it makes 48p!

[bioking] 02/7/2019 12:41

A stock like FUM with close Phase 3 readout for a potential Blockbuster would be valued closer to $500 million by now in USA . Its unbelievable that FUM is still valued less than 100 million the upfront payment from a potential partner alone could be in that level .I still think buyout is more likely because its cheaper than to pay high royalties and milestones . LOVE IT

[bg23] 02/7/2019 12:29

2cbg.......... wd, is that foresight or pig-headed stubbornness?? I need 48p and I can tell you ahead of time it is 'outright stubbornness' !! your big decision now is surely, 'cut and run' or 'believe'.......not sure where I stand on that !! although I do feel a little silly ignoring the recent research and not adding, but then again I didn't take part in the fundraising earlier this year which was a little foolish. good luck whatever you decide

[2cbg] 02/7/2019 12:12

I totally agree SOLis - JB needs to smile and learn some presentation skills. Anyway, after 3 years in FUM I finally broke even today!!

[j777j] 02/7/2019 11:38

Must be on the radar of biofunds across the pond.

[mikethebike4] 02/7/2019 11:19

large trade in the states (famdf)

[j777j] 02/7/2019 09:34

The markets that Futura's ED and topical pain gels are targeting, are in excess of $12 billion pa. If they only get a small market share with 15% royalties,the numbers are massive. On top of that the previous broker had factored in a total of $90 million in upfront and milestone payments for the med gel.

[jaws6] 02/7/2019 09:12

seen this today hxxps://www.pro activeinvestors.co.uk/companies/stocktube/13946/futura-medical-plc---elevator-pitch-13946.html

[j777j] 01/7/2019 13:41

The game changer is that the TPR pain gels penetrate up to 10 times faster that currently available drugs. This means not only do they work much faster but should enable the application to be cut from say 4xday to 2x day.

[rrr] 01/7/2019 13:19

J777J 'I agree and it is actually twice the size of the ED market.' I'm not too surprised by that. Arthritis of the knee, say, not bad enough for an op, or maybe the patient too unfit for surgery, but very debilitating and painful. Lots of potentially very unpleasant side effects, some very serious, from oral NSAIDs. Try morphine or similar instead? again side effects are marked and of course they're addictive. So an effective topical NSAID such as TPR100, with reduced risk of systemic side effects, will be a valuable and welcome addition to the therapeutic armoury.

[j777j] 01/7/2019 13:11

That was on top of $75 million paid upfront after only a phase 2 study. "Lilly agreed to pay Icos, a biotechnology start-up company that owns the rights to the drug, an up-front fee of $75 million. Analysts said that amount was extremely high for a drug that had not yet entered the final, and most important, phase of clinical trials. In another unusual arrangement, the two companies will share the marketing and sales of the drug in North America and in Europe and split the profits 50-50."

[j777j] 01/7/2019 11:58

I agree and it is actually twice the size of the ED market. Liberum did not even include it in their last report. Topical Pain Relief Market to Reach $13.27 Bn, Globally, by 2025 Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines facilitate the growth in the global topical pain relief industry. Non-opioids segment is likely to be lucrative from 2018 to 2025. Over-the-counter pain relief segment to lead in terms of revenue and growth by 2025. E-commerce segment to register the highest growth rate by 2025. Asia-Pacific to grow the fastest during the forecast period

[rrr] 01/7/2019 11:20

Don't forget TPR100: TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism Marketing authorisation application by UK commercialisation partner, Thornton & Ross (a subsidiary of STADA AG) submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2018. Ongoing commercial discussions with several potential distribution partners for other territories. Any further licensing deals are expected to be after UK regulatory approval. TPR100 - Post year end Supporting Thornton & Ross on responses to initial MHRA feedback received in February 2019. hTTps://www.futuramedical.com/content/news/archive19/100419.asp

[tiananmen] 01/7/2019 10:57

I meant over the next day or two.

[j777j] 01/7/2019 10:35

I am particularly interested in the 56p level,where a lot of investors bought shares.

[tiananmen] 01/7/2019 10:31

44p target next

[j777j] 01/7/2019 09:26

Huge and growing marketplace. Where viagra at launch became the fastest prescription product ever launched. Med2005 works in 5 to 10 mins v up to one hour. Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024. Inetresting to note how much larger the market is (double the size,) according to independent research is,compared to the Liberum forecast where the see 140p as level if trials are complete success. So that number could turn out to be conservative.

[glavey] 01/7/2019 09:04

No matter how much medication is applied at some point it will loose its effectiveness.